Clinical Trial

Long-term Outcomes of Prostate Cancer Screening

Study acronym: STHLM3MRI_3
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.
Trial Details
NCT Number NCT07155759
Lead Sponsor Karolinska Institutet
Collaborators: Swedish Cancer Foundation, The Swedish Research Council
Conditions Prostate Cancer
Enrollment 7,500 participants
Start Date 2024-11-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2035-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-04